Related Experiment Videos
Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update
Nanping Wang1, Ruiying Yin, Yan Liu
1Key Laboratory of Molecular Cardiovascular Sciences at Peking University, Beijing, 100191, China. nanpingwang2003@yahoo.com
Abstract:
Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the ligand-activated nuclear receptor family. Thiazolidinediones, such as rosiglitazone and pioglitazone, are synthetic agonists selective for PPARγ and have been used in the clinical treatment of type 2 diabetes. However, beyond the metabolic effects on glycemic control, PPARγ and its ligands also have profound effects on cardiovascular biological and pathophysiological processes. As cardiovascular diseases are closely associated with insulin resistance, and the major cause of death and complications of type 2 diabetes, a comprehensive understanding of the cardiovascular roles of this receptor is critical for the rational application of the existing agonists and the future development of therapeutic modulators. Therefore, this review will focus on the recent advances regarding the cardiovascular functions of PPARγ and its recognized effects on major cardiovascular diseases, in particular, atherosclerosis and associated processes.
Related Concept Videos
Peroxisomes
Peroxisomes
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Coronary Artery Disease II: Pathophysiology